# Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency

> **NCT00191165** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 27 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** Somatropin
- **DRUG:** Somatropin

## Key facts

- **NCT ID:** NCT00191165
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2009-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191165, "Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00191165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*